Clinical reference Biomarker Directory
Back to directory

N-terminal propeptide of type 1 procollagen

Established

P1NP is the leading bone formation marker, used to monitor both anabolic and antiresorptive osteoporosis therapy.

Also known as P1NP procollagen type 1 N-terminal propeptide
In plain language

P1NP measures how fast new bone is being built. Doctors watch it after starting bone-building osteoporosis drugs to make sure it's rising as expected, which is the opposite of what should happen with the more common bone-thinning-slowing drugs.

Biomarker & context

P1NP is a byproduct released when new type I collagen is formed during bone building, serving as the leading marker of bone formation activity, complementary to resorption markers like CTX.

What it indicates

P1NP levels reflect the rate of new bone formation; it is used to monitor osteoporosis treatment response, with a distinctive expected pattern depending on drug class — P1NP should rise with anabolic (bone-building) drugs like teriparatide, but fall with antiresorptive drugs like bisphosphonates.

Diagnosis & clinical testing

Measured via serum immunoassay, typically alongside CTX (a resorption marker) for a complete bone-turnover picture; a substantial rise in P1NP after starting an anabolic osteoporosis drug confirms the expected pharmacologic effect.

Guiding treatment

P1NP is used to confirm adequate response to anabolic osteoporosis therapy and, alongside CTX, to monitor antiresorptive treatment adherence and effectiveness over the first 3-6 months of therapy.

Clinical significance

Expected direction of change differs by drug class — rising with anabolic drugs, falling with antiresorptive drugs.

References
  1. Cleveland Clinic Journal of Medicine. (2023). Making best use of bone turnover markers to monitor oral bisphosphonate therapy.